Trump's inauguration drew several business and tech CEOs, including Jeff Bezos, Mark Zuckerberg, Elon Musk, Tim Cook, and TikTok's Shou Zi Chew.

Open AI’s Sam Altman and TikTok CEO Shou Zi Chew were ... partially obscured) and Amazon's Jeff Bezos were spotted together at a pre-inauguration service at St. John's Church in Washington ...

About 20,000 Trump supporters have gathered at Capital One Arena in Washington Monday afternoon, where Trump and Vice President JD Vance are expected to address the crowd later in the day. Trump is also expected to sign several executive actions at the area during his on-stage appearance.

Tesla CEO Elon Musk, Meta CEO Mark Zuckerberg, Amazon founder Jeff Bezos and OpenAI CEO Sam Altman will all attend President-elect Trump's inauguration, a source familiar with the planning who was ...

World’s-richest-man Elon Musk, Meta CEO Mark Zuckerberg, and Amazon chief Jeff Bezos are slated to attend the forty-seventh president’s inauguration next week, according to NBC News. The tech trio will be seated alongside elected officials and Trump’s Cabinet selections.

The inauguration guestlist features unlikely names including MMA fighter Conor McGregor and influencer Jake Paul.

Some of the nation's most prominent technology industry CEOs are planning to attend President-elect Donald Trump's inauguration.

Amazon founder Jeff Bezos has also adjusted his stance toward Trump. Despite a contentious history involving disputes over federal contracts and criticism of The Washington Post, Bezos has shown ...

ABC News has live coverage of the inauguration of President Trump beginning at 6 a.m. until approximately 11 p.m.

Donald Trump’s 2025 inaugural entourage was noticeably more flush than the crowd at his first presidential ceremony, with the attendees’ total net worth approaching $1.2 trillion. The New Republic broke down the net worths of the attendees with the biggest pockets.

A Midtown-based therapeutics company hopes to tap the growing market of anti-aging drugs with a suite of pharmaceutical research, and investors are taking notice. Cambrian Bio recently raised $23 million to advance its portfolio of drug discovery platforms focused on the biological processes that break down with age.